Development and Optimization of Eberconazole Nanostructured Lipid Carrier Topical Formulations Based on the QbD Approach
Apr 16, 2026
47'%3e%3cpath%20d='M7.49967%2017.5H14.9997C15.6913%2017.5%2016.283%2017.0833%2016.533%2016.4833L19.0497%2010.6083C19.1247%2010.4166%2019.1663%2010.2166%2019.1663%209.99998V8.33331C19.1663%207.41665%2018.4163%206.66665%2017.4997%206.66665H12.2413L13.033%202.85831L13.058%202.59165C13.058%202.24998%2012.9163%201.93331%2012.6913%201.70831L11.808%200.833313L6.31634%206.32498C6.01634%206.62498%205.83301%207.04165%205.83301%207.49998V15.8333C5.83301%2016.75%206.58301%2017.5%207.49967%2017.5ZM7.49967%207.49998L11.1163%203.88331L9.99967%208.33331H17.4997V9.99998L14.9997%2015.8333H7.49967V7.49998ZM0.833008%207.49998H4.16634V17.5H0.833008V7.49998Z'%20fill='%232E323C'%20fill-opacity='0.6'/%3e%3c/g%3e%3cdefs%3e%3cclipPath%20id='clip0_like_meta'%3e%3crect%20width='20'%20height='20'%20fill='white'/%3e%3c/clipPath%3e%3c/defs%3e%3c/svg%3e){kind=small}
0
Upload by HazelBookmark
Share
More Options
Fullscreen
This document is user-generated content (UGC). WPS Office is not responsible for its accuracy or copyright. If you believe this content violates your rights, please use the button.